Physician profile
Tait Dell Olaveson
NPI 1356518831
$41,694.75
in general payments reported to CMS, 2019-2025
15 companies · $32K in 2025
The $32K reported for 2025 was more than what 98% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2021: $75.90 · 2022: $133 · 2023: $8,631 · 2024: $167 · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,072 · Travel and Lodging: $6,764 · Food and Beverage: $2,161 · Education: $1,514 · Honoraria: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,125.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,071.86 |
| Travel and Lodging | $6,764.37 |
| Food and Beverage | $2,160.55 |
| Education | $1,513.70 |
| Honoraria | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Access Pro Medical, LLC | $40,347.34 | 2023-2025 | Matriderm, Matriderm |
| Integra Lifesciences Corporation | $343.66 | 2019-2022 | |
| Avita Medical Americas, LLC | $242.76 | 2019-2025 | Recell, Cohealyx, Permeaderm |
| Kerecis Limited | $196.96 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Vericel Corporation | $109.20 | 2022-2025 | Nexobrid, Epicel (Cultured Epidermal Autografts) |
| Boston Scientific Corporation | $96.99 | 2025 | Spyglass Discover |
| Tela Bio, INC. | $95.68 | 2023-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Davol INC. | $71.53 | 2019-2022 | |
| Haemonetics Corporation | $55.87 | 2022-2024 | Teg6s Hemostasis System |
| Atricure, INC. | $38.14 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Medical Device Business Services, INC. | $23.43 | 2019 | |
| Shire North American Group INC | $20.12 | 2019 | |
| Portola Pharmaceuticals, LLC | $19.14 | 2019 | |
| Merck Sharp & Dohme LLC | $17.97 | 2019 | |
| Smith+Nephew, INC. | $15.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tait Olaveson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.